# A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

> **NCT07221084** · PHASE1 · COMPLETED · sponsor: **Crinetics Pharmaceuticals Inc.** · enrollment: 21 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Atumelnant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07221084
- **Lead sponsor:** Crinetics Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-28
- **Primary completion:** 2026-02-07
- **Final completion:** 2026-02-27
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07221084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07221084, "A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07221084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*